ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2371

Predict Hyperkalemia in Advanced CKD Patients Using Machine Learning Algorithms

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Chang, Hsin-Hsiung, Paochien Hospital, Pingtung, Taiwan
  • Wu, Chia-Lin, Changhua Christian Hospital, Changhua, Changhua, Taiwan
Background

Hyperkalemia is a common and fatal problem in advanced chronic kidney disease patients. The incidence rate was about 40-50%. It may cause muscle weakness, paralysis, and even cardiac arrhythmia. Our goal is to develop machine learning models to predict hyperkalemia in advanced chronic kidney disease patients, which could help physicians make clinical decisions.

Methods

We collected clinical data for advanced CKD (CKD stage 4 and 5, eGFR < 30 ml/min/1.73m2) patients receiving Output Patient Care in one medical center in Taiwan from January 2010 to December 2019. 1,965 patients were included. Four machine learning models (multilayer perceptron [MLP], logistic regression with regularization, XGBoost, and random forest [RF]) were used to estimate serum potassium concentration 3 months later. 2 Nephrologists participated in human-machine competition.Area under the receiver operating characteristic curves (AUCs), sensitivity, specificity, positive (PPV) and negative (NPV) predicted values, and accuracy were used to evaluate
the performance of machine learning models with that of these physicians.

Results

In a test set including 2,074 records, the AUC of machine learning models was highest for XGBoost (0.843; 95% confidence interval [CI], 0.822–0.864). Moreover, the NPV and specificity were 0.875 and 0.943, respectively. The AUC for detecting hyperkalemia by humans was 0.602, 95% CI, 0.580–0.623. XGBoost model performed significantly better than humans (P < 0.001, using the DeLong test).

Conclusion

Machine learning models may help physicians make clinical decisions in advanced CKD patients who suffer from hyperkalemia in outpatient department care and possibly reduce cardiac arrhythmia.